Sep 18 |
Sellas Life Sciences Group Inc (NASDAQ:SLS): A Bull Case Theory
|
Aug 13 |
SELLAS Life Sciences GAAP EPS of -$0.13 beats by $0.04
|
Aug 13 |
SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update
|
Aug 6 |
SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas
|
Jul 31 |
SELLAS Life Sciences announces $21M registered direct offering
|
Jul 31 |
SELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to Market
|
Jul 16 |
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia
|
Jul 8 |
SELLAS' SLS009 granted orphan drug designation by EMA for acute myeloid leukemia treatment
|
Jul 8 |
SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia
|
Jun 24 |
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia
|